respiratory

Sales & Marketing

12 Questions with Shauna Lord

Shauna Lord recently joined GSK as Business Unit Head Specialty (UK Commercial) to lead the Specialty business in the UK.

News

Infex chases after Insmed with bronchiectasis trial win

UK biotech Infex is in hot pursuit of Insmed's Brinsupri, the only approved therapy for non-CF bronchiectasis, with its quarterly-dosed antibody.

News

AZ is three for three with COPD hope tozorakimab

AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.

News

Pulmonary fibrosis drug developer Avalyn files IPO

Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.

News

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

News

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

12 Questions with Shauna Lord

Infex chases after Insmed with bronchiectasis trial win

AZ is three for three with COPD hope tozorakimab

Pulmonary fibrosis drug developer Avalyn files IPO

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Where others missed, AZ's IL-33 drug hits the mark in COPD

Drugmakers asked to defend Chinese trials; reports

Discover a new era of healthcare panel engagement: Grounded ...

respiratory

Editor's Picks